Lake Street Initiates Coverage On Journey Medical with Buy Rating, Announces Price Target of $9
Benzinga Newsdesk 2 years ago
NewsPrice TargetInitiationAnalyst Ratings
Lake Street analyst Thomas Flaten initiates coverage on Journey Medical (NASDAQ:DERM) with a Buy rating and announces Price Target of $9.
Lake Street analyst Thomas Flaten initiates coverage on Journey Medical (NASDAQ:DERM) with a Buy rating and announces Price Target of $9.